Description: <b>Phenolic acid</b> found in gallnuts, sumac, witch hazel, tea leaves, oak bark. Has antioxidant, antimicrobial and anti-obesity properties.<br>
The GA derivatives include two types: ester and catechin derivatives. The most common ester derivatives of GA are alkyl esters, which are composed mainly of methyl gallate (MG), propyl gallate (PG), octyl gallate (OG), dodecyl gallate (DG), tetradecyl gallate (TG), and hexadecyl gallate (HG), and some of the main catechin derivatives are epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC), gallocatechin gallate (GCG), and epigallocatechin gallate (EGCG)<br>
<br>
Gallic acid is a naturally occurring polyphenol found in a variety of plant-based foods. Some of the best dietary sources include:<br>
<br>
Fruits:<br>
Berries (strawberries, blackberries, blueberries)<br>
Grapes, including red wine (grapes are rich in polyphenols)<br>
Pomegranates and apples<br>
Nuts and Seeds: Walnuts and almonds have been noted to contain GA in their skins<br>
Herbs and Spices: Tea (especially green tea), Sumac and other spices<br>
Other Plants: Gallnuts (from oak trees)<br>
<br>
Pathways:<br>
-ROS generation in tumor cells is frequently reported, Antioxidant behavior dominates in normal tissue models
-Apoptosis Induction: Activating caspase cascades, Shifting Bax versus Bcl-2, MMP, cyt-c release
-Cell Cycle Arrest: typ @ G1 or G2/M checkpoints. <br>
-Anti-inflammatory Effects: inhibiting NF-κB <br>
-reported Angiogenesis Inhibition:<br>
-Modulation of Signaling Pathways: MAPK Pathway, PI3K/Akt Pathway Inhibition, p53 Pathway<br>
<br>
Gallic acid exhibits a complex behavior with ROS in cancer cells, acting as both an antioxidant and a pro-oxidant depending on the context and its concentration:<br>
<br>
Antioxidant Effects at Low Doses:<br>
-At lower concentrations, gallic acid is typically characterized by its ability to scavenge free radicals, thus reducing oxidative stress.<br>
This antioxidant property may help protect normal cells from DNA damage, reducing the risk of mutations that could lead to cancer.<br>
<br>
Pro-oxidant Effects at High Doses: >50-100uM?<br>
-Capable of biphasic redox behavior (antioxidant in normal cells, pro-oxidant in some tumor contexts)
-At higher concentrations, GA can exert pro-oxidant effects, generating ROS within cancer cells.
Elevated ROS levels can overwhelm the cellular antioxidant defenses of cancer cells, leading to oxidative stress, mitochondrial dysfunction, and ultimately cell death.<br>
<br>
Oral bioavailability is well absorbed but subject to rapid conjugation (glucuronide/sulfate/methylated metabolites). Many cytotoxic in-vitro concentrations are in the 10–100 µM range, often higher than typical plasma levels after dietary intake.<br>
<br>
<p><b>Gallic acid</b> — Gallic acid is a naturally occurring trihydroxybenzoic phenolic acid and plant secondary metabolite with antioxidant, pro-oxidant, anti-inflammatory, antimicrobial, and extensively studied preclinical anticancer activity. It is formally classified as a low-molecular-weight polyphenolic phenolic acid and is commonly abbreviated GA. Its chemical identity is 3,4,5-trihydroxybenzoic acid. Dietary and botanical sources include gallnuts, sumac, tea, grapes, berries, pomegranate, mango, walnuts, oak bark, and hydrolysable tannins. GA is also released during digestion or microbial metabolism of gallotannins and galloylated polyphenols. Its anticancer effects are strongly concentration-, cell-type-, redox-, and exposure-dependent.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Biphasic redox modulation, with ROS generation and oxidative stress predominating in susceptible cancer cells at cytotoxic concentrations, but ROS scavenging and NRF2-linked antioxidant protection predominating in many normal or inflamed tissues.</li>
<li>Mitochondrial apoptosis through mitochondrial membrane depolarization, Bax/Bcl-2 imbalance, cytochrome-c release, caspase activation, and PARP cleavage.</li>
<li>Suppression of oncogenic survival signaling, particularly PI3K/AKT, STAT3, EGFR, and context-dependent MAPK signaling.</li>
<li>Cell-cycle arrest through modulation of p53, p21, p27, cyclins, and cyclin-dependent kinases, commonly at G1 or G2/M depending on the model.</li>
<li>Suppression of inflammatory and tumor-promoting transcription through NF-κB inhibition and reduced COX-2, IL-6, TNF-α, and related mediators.</li>
<li>Inhibition of angiogenesis through PTEN/AKT/HIF-1α/VEGF signaling and reduced endothelial or tumor-associated vascular responses.</li>
<li>Suppression of invasion, migration, epithelial-mesenchymal transition, and matrix-remodelling pathways, including MMP2, MMP9, Wnt/β-catenin, and selected EMT regulators.</li>
<li>Metabolic disruption through context-dependent inhibition of glycolysis, LDH-associated lactate metabolism, lipid synthesis, and other tumor bioenergetic processes.</li>
<li>Therapy sensitization reported with selected cytotoxic and targeted agents, including paclitaxel, carboplatin, camptothecin, and olaparib, but currently supported mainly by cell-culture evidence.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> GA can be absorbed orally and is among the more readily absorbed simple polyphenols, but absorption is followed by rapid methylation, glucuronidation, sulfation, microbial transformation, and urinary elimination. Circulating exposure consists substantially of conjugated and microbial metabolites rather than persistent free GA. Formulation strategies such as nanoparticles, conjugates, and encapsulation can increase exposure experimentally, but these delivery systems remain investigational.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments use approximately 10–100 µM GA, with pronounced pro-oxidant cytotoxicity frequently occurring toward the upper portion of this range or above it. These free-compound concentrations commonly exceed sustained plasma concentrations expected from ordinary dietary intake. Consequently, direct systemic anticancer effects demonstrated at high micromolar exposure may not be achievable through food consumption or conventional oral supplementation. Local gastrointestinal exposure, metabolites, tissue accumulation, or engineered delivery could produce different exposure relationships.</p>
<p><b>Clinical evidence status:</b> Preclinical. GA has extensive cell-culture evidence and a smaller body of animal evidence across multiple tumor types. Human pharmacokinetic and food-intervention studies confirm exposure to GA and its metabolites, but isolated GA has not established anticancer efficacy in randomized clinical trials and is not an approved cancer therapy. Human studies involving polyphenol-rich mango, pomegranate, tea, grape, or botanical preparations cannot be attributed specifically to GA. Therapy-sensitizing activity remains experimental and should not be used to justify combining GA supplements with chemotherapy outside clinical supervision.</p>
<h3>Gallic Acid Mechanistic Profile</h3>
<table border="1" cellpadding="4" cellspacing="0">
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Biphasic redox modulation</td>
<td>ROS ↑; oxidative stress ↑ (dose-dependent) (model-dependent)</td>
<td>ROS ↓; radical scavenging ↑; antioxidant capacity ↑</td>
<td>P, R</td>
<td>Selective redox destabilization</td>
<td>Pro-oxidant tumor effects are most evident at higher in-vitro concentrations; antioxidant effects dominate in many non-malignant injury models.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis</td>
<td>Mitochondrial membrane potential ↓; Bax ↑; Bcl-2 ↓; cytochrome-c ↑; caspases ↑; PARP cleavage ↑</td>
<td>↔ or apoptosis ↓ under oxidative injury (context-dependent)</td>
<td>R, G</td>
<td>Intrinsic apoptotic cell death</td>
<td>Frequently downstream of ROS accumulation, although mitochondrial and apoptotic responses vary by tumor genotype and concentration.</td>
</tr>
<tr>
<td>3</td>
<td>PI3K AKT survival signaling</td>
<td>PI3K ↓; p-AKT ↓; mTOR signaling ↓ (model-dependent); PTEN ↑</td>
<td>↔ or AKT-associated cytoprotection ↑ during inflammatory injury</td>
<td>R, G</td>
<td>Growth and survival suppression</td>
<td>Direction can differ between malignant cells and stressed normal tissues; pathway effects should be entered with context qualifiers.</td>
</tr>
<tr>
<td>4</td>
<td>Cell-cycle checkpoints</td>
<td>p53 ↑; p21 ↑; p27 ↑; cyclin D1 ↓; cyclin E ↓; G1 or G2/M arrest ↑</td>
<td>↔</td>
<td>G</td>
<td>Cytostasis</td>
<td>Arrest phase is model-dependent and should not be generalized to one checkpoint.</td>
</tr>
<tr>
<td>5</td>
<td>NF-κB inflammatory signaling</td>
<td>NF-κB ↓; COX-2 ↓; IL-6 ↓; TNF-α ↓; pro-survival inflammation ↓</td>
<td>NF-κB ↓; inflammatory cytokines ↓; epithelial protection ↑</td>
<td>R, G</td>
<td>Anti-inflammatory and anti-survival signaling</td>
<td>One of the more reproducible effects across tumor and non-tumor inflammatory models.</td>
</tr>
<tr>
<td>6</td>
<td>MAPK stress signaling</td>
<td>JNK ↑; p38 ↑; ERK ↓ or ↔ (context-dependent)</td>
<td>Pathologic p38 and ERK activation ↓ or protective signaling ↑ (context-dependent)</td>
<td>P, R</td>
<td>Stress-response reprogramming</td>
<td>MAPK direction depends on cell type, initiating stress, exposure duration, and whether apoptosis or cytoprotection is being measured.</td>
</tr>
<tr>
<td>7</td>
<td>Angiogenesis and hypoxia signaling</td>
<td>PTEN ↑; AKT ↓; HIF-1α ↓; VEGF ↓; angiogenesis ↓</td>
<td>↔</td>
<td>G</td>
<td>Anti-angiogenic activity</td>
<td>Supported by selected ovarian, cervical, and other experimental cancer models; not clinically validated.</td>
</tr>
<tr>
<td>8</td>
<td>Invasion and epithelial-mesenchymal transition</td>
<td>MMP2 ↓; MMP9 ↓; Wnt/β-catenin ↓; EMT ↓; migration ↓; invasion ↓</td>
<td>↔ or epithelial barrier integrity ↑</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Often secondary to NF-κB, AKT, MAPK, and Wnt pathway modulation.</td>
</tr>
<tr>
<td>9</td>
<td>NRF2 antioxidant response</td>
<td>NRF2 ↑ or ↓ (context-dependent); HO-1 ↑ or ↓; redox adaptation altered</td>
<td>NRF2 ↑; HO-1 ↑; GSH ↑; SOD ↑; catalase ↑</td>
<td>R, G</td>
<td>Secondary redox adaptation</td>
<td>NRF2 activation is generally cytoprotective in normal tissue but may protect some cancers; prostate-cancer findings indicate model-dependent alteration of the NRF2 HO-1 BACH1 axis.</td>
</tr>
<tr>
<td>10</td>
<td>Glycolysis and lipid metabolism</td>
<td>LDH activity ↓; lactate production ↓; FASN ↓; glycolytic dependence ↓ (model-dependent)</td>
<td>↔</td>
<td>R, G</td>
<td>Metabolic growth restriction</td>
<td>The evidence base is smaller and less consistent than that for redox modulation and apoptosis; avoid treating glycolysis inhibition as universal.</td>
</tr>
<tr>
<td>11</td>
<td>DNA damage and repair balance</td>
<td>DNA damage ↑; p53 response ↑; FEN1 ↓ in nanoparticle studies; repair capacity ↓ (model-dependent)</td>
<td>Oxidative DNA damage ↓ at antioxidant exposure</td>
<td>R, G</td>
<td>Genotoxic stress in cancer cells</td>
<td>Free GA and GA-containing nanocarriers are not mechanistically interchangeable; nanoparticle-specific findings require separate qualification.</td>
</tr>
<tr>
<td>12</td>
<td>Chemosensitization</td>
<td>Paclitaxel response ↑; carboplatin response ↑; camptothecin response ↑; olaparib response ↑ (model-dependent)</td>
<td>Chemotherapy-associated injury ↓ or ↔ in limited models</td>
<td>G</td>
<td>Adjunctive treatment sensitization</td>
<td>Evidence is primarily in vitro. Both antioxidant protection and pro-oxidant sensitization are possible, making unsupervised clinical combinations inappropriate.</td>
</tr>
<tr>
<td>13</td>
<td>Immune checkpoint and tumor immunity</td>
<td>PD-L1 ↓; CD8-positive T-cell activity ↑; antitumor immune response ↑ (model-dependent)</td>
<td>Immune homeostasis modulation ↔</td>
<td>G</td>
<td>Immune sensitization</td>
<td>Promising animal evidence exists, but direct clinical immunotherapy enhancement has not been demonstrated.</td>
</tr>
<tr>
<td>14</td>
<td>Clinical Translation Constraint</td>
<td>Free systemic GA exposure ↓; conjugation ↑; metabolism ↑; cytotoxic target exposure often not reached</td>
<td>Dietary exposure generally tolerated; high-dose isolated exposure insufficiently characterized</td>
<td>R, G</td>
<td>Exposure and evidence limitation</td>
<td>Rapid metabolism, uncertain tumor delivery, formulation heterogeneity, high in-vitro concentrations, and absence of isolated-GA cancer trials limit translation.</td>
</tr>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>